CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 250 of 308 entries

View as:

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

Phase: N/A Priority: Normal

NCT ID: NCT00051935 Org: User:

Start: 01/31/03 End: 10/31/03 Due: 10/31/04

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Phase: N/A Priority: Normal

NCT ID: NCT00548405 Org: User:

Start: 10/31/07 End: 09/30/11 Due: 09/30/12

A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal

NCT ID: NCT00750334 Org: User:

Start: 09/30/08 End: 10/31/08 Due: 10/31/09

Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00753675 Org: User:

Start: 10/31/08 End: 09/30/12 Due: 09/30/13

A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal

NCT ID: NCT00002348 Org: User:

Start: - End: - Due: -

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea

Phase: N/A Priority: Normal

NCT ID: NCT00196794 Org: User:

Start: 04/30/05 End: 08/31/07 Due: 08/31/08

Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT00068211 Org: User:

Start: 08/31/03 End: 01/31/06 Due: 01/31/07

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01876784 Org: User:

Start: 09/17/13 End: 01/22/22 Due: 01/22/23

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

Phase: N/A Priority: Normal

NCT ID: NCT02782741 Org: User:

Start: 11/02/16 End: 05/31/23 Due: 05/31/24

A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee

Phase: N/A Priority: Normal

NCT ID: NCT00131352 Org: User:

Start: 05/31/05 End: 09/30/06 Due: 09/30/07

SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT00004049 Org: User:

Start: 04/30/99 End: - Due: -

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization

Phase: N/A Priority: Normal

NCT ID: NCT00291811 Org: User:

Start: 10/31/03 End: - Due: -

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Phase: N/A Priority: Normal

NCT ID: NCT02205489 Org: User:

Start: 10/31/14 End: 04/30/16 Due: 04/30/17

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Phase: N/A Priority: Normal

NCT ID: NCT00665314 Org: User:

Start: 11/30/07 End: 06/30/09 Due: 06/30/10

Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC

Phase: N/A Priority: Normal

NCT ID: NCT00496275 Org: User:

Start: 08/31/06 End: 05/31/07 Due: 05/31/08

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

Phase: N/A Priority: Normal

NCT ID: NCT01074944 Org: User:

Start: 06/30/10 End: 10/31/15 Due: 10/31/16

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

Phase: N/A Priority: Normal

NCT ID: NCT00418600 Org: User:

Start: 11/30/06 End: 08/31/07 Due: 08/31/08

Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients

Phase: N/A Priority: Normal

NCT ID: NCT01722526 Org: User:

Start: 03/31/13 End: 01/31/14 Due: 01/31/15

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Phase: N/A Priority: Normal

NCT ID: NCT00597116 Org: User:

Start: 12/31/07 End: 01/31/10 Due: 01/31/11

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

Phase: N/A Priority: Normal

NCT ID: NCT00418886 Org: User:

Start: 01/31/07 End: 02/14/23 Due: 02/14/24

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

Phase: N/A Priority: Normal

NCT ID: NCT00146757 Org: User:

Start: 10/31/02 End: 05/31/05 Due: 05/31/06

Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies

Phase: N/A Priority: Normal

NCT ID: NCT02536755 Org: User:

Start: 10/27/15 End: 06/24/21 Due: 06/24/22

Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration

Phase: N/A Priority: Normal

NCT ID: NCT00196729 Org: User:

Start: 12/31/01 End: 09/30/03 Due: 09/30/04

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Phase: N/A Priority: Normal

NCT ID: NCT00741780 Org: User:

Start: 06/30/06 End: 07/31/11 Due: 07/31/12

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Phase: N/A Priority: Normal

NCT ID: NCT01288027 Org: User:

Start: 06/30/11 End: 12/31/13 Due: 12/31/14

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II	NCT00051935	Genzyme, a Sanofi Company	user2@example.com	None	2003-01-31	2003-10-31	2004-10-31	-	-	2025-07-14
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two	NCT00548405	Genzyme, a Sanofi Company	user2@example.com	None	2007-10-31	2011-09-30	2012-09-30	-	-	2025-07-14
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)	NCT00750334	Genzyme, a Sanofi Company	user2@example.com	None	2008-09-30	2008-10-31	2009-10-31	-	-	2025-07-14
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer	NCT00753675	Genzyme, a Sanofi Company	user2@example.com	None	2008-10-31	2012-09-30	2013-09-30	-	-	2025-07-14
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma	NCT00002348	Genzyme, a Sanofi Company	user2@example.com	None	-	-	-	-	-	2025-07-14
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea	NCT00196794	Genzyme, a Sanofi Company	user2@example.com	None	2005-04-30	2007-08-31	2008-08-31	-	-	2025-07-14
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma	NCT00068211	Genzyme, a Sanofi Company	user2@example.com	None	2003-08-31	2006-01-31	2007-01-31	-	-	2025-07-14
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer	NCT01876784	Genzyme, a Sanofi Company	user2@example.com	None	2013-09-17	2022-01-22	2023-01-22	-	-	2025-07-14
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease	NCT02782741	Genzyme, a Sanofi Company	user2@example.com	None	2016-11-02	2023-05-31	2024-05-31	-	-	2025-07-14
A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee	NCT00131352	Genzyme, a Sanofi Company	user2@example.com	None	2005-05-31	2006-09-30	2007-09-30	-	-	2025-07-14
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors	NCT00004049	Genzyme, a Sanofi Company	user2@example.com	None	1999-04-30	-	-	-	-	2025-07-14
Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization	NCT00291811	Genzyme, a Sanofi Company	user2@example.com	None	2003-10-31	-	-	-	-	2025-07-14
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	NCT02205489	Genzyme, a Sanofi Company	user2@example.com	None	2014-10-31	2016-04-30	2017-04-30	-	-	2025-07-14
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).	NCT00665314	Genzyme, a Sanofi Company	user2@example.com	None	2007-11-30	2009-06-30	2010-06-30	-	-	2025-07-14
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC	NCT00496275	Genzyme, a Sanofi Company	user2@example.com	None	2006-08-31	2007-05-31	2008-05-31	-	-	2025-07-14
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)	NCT01074944	Genzyme, a Sanofi Company	user2@example.com	None	2010-06-30	2015-10-31	2016-10-31	-	-	2025-07-14
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis	NCT00418600	Genzyme, a Sanofi Company	user2@example.com	None	2006-11-30	2007-08-31	2008-08-31	-	-	2025-07-14
Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients	NCT01722526	Genzyme, a Sanofi Company	user2@example.com	None	2013-03-31	2014-01-31	2015-01-31	-	-	2025-07-14
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma	NCT00597116	Genzyme, a Sanofi Company	user2@example.com	None	2007-12-31	2010-01-31	2011-01-31	-	-	2025-07-14
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients	NCT00418886	Genzyme, a Sanofi Company	user2@example.com	None	2007-01-31	2023-02-14	2024-02-14	-	-	2025-07-14
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old	NCT00146757	Genzyme, a Sanofi Company	user2@example.com	None	2002-10-31	2005-05-31	2006-05-31	-	-	2025-07-14
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies	NCT02536755	Genzyme, a Sanofi Company	user2@example.com	None	2015-10-27	2021-06-24	2022-06-24	-	-	2025-07-14
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration	NCT00196729	Genzyme, a Sanofi Company	user2@example.com	None	2001-12-31	2003-09-30	2004-09-30	-	-	2025-07-14
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).	NCT00741780	Genzyme, a Sanofi Company	user2@example.com	None	2006-06-30	2011-07-31	2012-07-31	-	-	2025-07-14
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa	NCT01288027	Genzyme, a Sanofi Company	user2@example.com	None	2011-06-30	2013-12-31	2014-12-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance